PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
The prognosis of extensive-stage small cell lung cancer is still very poor, even for those
who received platinum-based chemotherapy and chest radiotherapy. 2-year survival rate of
these patients is only about 10%. Therefore, this study aims to explore a comprehensive
treatments with low toxicity to further improve the efficacy for these paitents with PD-1
inhibitor.